House GOP Starts Crafting Health Care Bills in Anticipation of Retaking Majority

Rep. Brett Guthrie (R-Ky.) will run to chair the House E&C Committee next session--and is considered by some lobbyists as the favorite to win--if Republicans maintain control of the House.

The top Republicans on two U.S. House health subcommittees are leading a party effort to “craft legislative proposals that Republicans can advance after retaking the majority” in the November 2022 midterm elections. It is not known whether the group will

Read More »

340B Program Flexibilities to Continue As COVID-19 Emergency Extended

HHS Secretary Xavier Becerra this week extended the COVID-19 public health emergency until mid-October.

U.S. Health and Human Services (HHS) Secretary Xavier Becerra on Monday extended the COVID-19 national public health emergency (PHE) for another 90 days, to Oct. 17. The move extends 340B program flexibilities implemented during the pandemic’s early days.

In

Read More »

Biden Administration’s Proposal to Retain 340B Hospital Drug Payment Cuts Draws More Fire

Groups whose members include 340B hospitals yesterday slammed CMS for proposing to continue deep drug payment cuts to 340B hospitals.

Several groups whose members include 340B hospitals yesterday slammed the Biden administration’s proposal to continue the Trump administration’s huge cut in Medicare Part B reimbursement for hospitals’ 340B purchased drugs.

The new administration yesterday announced its proposed plans for

Read More »

One-Fourth of 340B DSH Hospitals at Risk of Losing Eligibility Due to Pandemic, Analysis Finds

Many hospitals reduced inpatient admissions during the COVID-19 pandemic. 340B hospitals now fear that this could cause them to lose their eligibility for 340B drug discounts due to changes in patient mix.

Roughly one out of four 340B disproportionate share (DSH) hospitals could lose their eligibility for 340B drug discounts due to COVID-19 pandemic-related changes in patient mix, an analysis of hospital Medicare cost reports for 2019 and 2020 shows. About one

Read More »

Help Wanted Ads Suggest HRSA Reorganization Is in Gear

Recent HRSA job postings suggest that a reorganization announced in late January is finally in motion.

There are signs that the U.S. Health Resources and Services Administration (HRSA) reorganization announced in late January is finally in motion. It is still unknown, though, if the 340B program is moving to a new home in the HRSA administrator’s

Read More »

Judge Consolidates Arguments in Two 340B Contract Pharmacy Lawsuits

A federal district judge will hold a joint hearing in October on drug makers’ Novartis and United Therapeutics’ 340B contract pharmacy lawsuits.

A federal district judge will hold a joint hearing in October on drug makers’ Novartis and United Therapeutics’ (UT) lawsuits challenging the government’s findings in May that the two companies’ 340B contract pharmacy policies are unlawful.

In a short unpublished

Read More »

United Therapeutics Fleshes Out its 340B Contract Pharmacy Legal Arguments

United Therapeutics told a judge on Friday that the government’s position that the company's 340B contract pharmacies are illegal “contravenes the plain text” of the 340B statute.

The government’s position that United Therapeutics’ (UT) restrictions on 340B contract pharmacies are illegal “contravenes the plain text” of the 340B statute, the drug company told a federal district judge on Friday.

The U.S. Health Resources and Services Administration’s (HRSA)

Read More »

Breaking News

In Surprise Move, Biden Administration Proposes Keeping Trump’s Nearly 30% Cut in 340B Hospitals’ Drug Reimbursement

The U.S. Centers for Medicare & Medicaid Services (CMS) said today it proposes to continue a nearly 30% reduction in Medicare Part B reimbursement for hospitals’ 340B-purchased drugs.

The Biden administration said today it proposes to continue a nearly 30% reduction in Medicare Part B reimbursement for hospitals’ 340B-purchased drugs.

The Trump administration implemented the payment reduction in January 2018. Hospital groups say it costs affected 340B hospitals

Read More »

Key Congressional Committee Urges HRSA to Fine Drug Makers Over 340B Contract Pharmacy Denials

U.S. House appropriators are encouraging HRSA to use fines and "any available measures" to hold drug manufacturers accountable for withholding 340B drug discounts.

The U.S. House Appropriations Committee is pleased with the U.S. Health Resources and Services Administration (HRSA) for challenging six drug makers’ denials of 340B pricing when covered entities use contract pharmacies, the committee said in a report released yesterday. It encouraged

Read More »

House Appropriators Want an Update from HRSA on its Plans to Clarify 340B Patient Definition and Provider Eligibility Criteria, Calls for New GAO Report

House appropriators want GAO to update its pivotal 2011 report on 340B, and want HRSA to report on its plans to implement the report's remaining two recommendations, which focus on clarifying eligibility criteria for 340B patients and providers.

In addition to weighing in on the ongoing 340B contract pharmacy standoff (see related story), the U.S. House Appropriations Committee has entered the thicket of the highly controversial topics of 340B patient definition and provider eligibility.

In its report

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report